Shares in Johnson & Johnson plunged yesterday as the company said the Puerto Rico plant that makes its blockbuster drug Eprex was the subject of a US regulatory investigation.
The US medical products and drug group said the Food and Drug Administration was likely to investigate litigation claims by a former plant employee. A fired maintenance worker claimed in a lawsuit that the company falsified records hiding manufacturing problems.
The FDA investigation concerned investors because the plant makes Eprex, an important drug for J&J and a target of intensified medical scrutiny because of its links to 141 deaths internationally.
J&J shares fell almost 13 per cent on the news, to $43.20 in lunchtime trading.
The news came as second-quarter earnings at Merck summed up one of the current woes of the US drug industry. The US group reported a decline in profits as core pharmaceuticals growth could not offset sales declines from drugs with expired patents.
In addition, the US healthcare industry has seen a crackdown on manufacturing quality standards by the FDA. The agency has taken note of problems at Eli Lilly and has fined Schering-Plough and Abbott Laboratories.
The J&J FDA probe raises the possibility that manufacturing problems could have played a part in the drug’s links to deaths.
Eprex is designed to boost red bloodcell production to fight anaemia: however, sometimes it causes pure red cell aspalsia, which inhibits bone marrow from making red bloodcells.
On Tuesday J&J said it was sending more warning letters to European doctors and stressed that only seven cases had been reported this year. It said the rare side-effect mainly arose with patients suffering chronic kidney failure.
The company sells Eprex outside the US only. Eprex and Procrit, the US version, are some of J&J’s most profitable products and had $3.8bn sales last year.
The FDA and the Justice Department declined to comment. Some analysts said it was likely the probe would amount to nothing. A New York Times report yesterday said the two agencies were conducting an investigation into the plant because of a lawsuit filed by boiler room employee Hector Arce, who was fired in 1999.
Merck reiterated that it expected no year-on-year earnings increase in 2002. It said this year was a transition year to get through the patent expiry damage. It expected at least 10 per cent sales growth in pharmaceuticals next year.
Merck has lost patent protection for a number of drugs, including Pepcid for ulcers. It had planned for Vioxx, a pain medication, to cover the gap. But sales have disappointed because of concerns over the drug’s safety and price.
Need Legal Help?
New York City, Long Island, New Jersey, and Florida
Our New York personal injury law firm is here to help you when you need it the most.